CA2325354A1 - Formes hautement actives de proteines du facteur de regulation de l'interferon - Google Patents

Formes hautement actives de proteines du facteur de regulation de l'interferon Download PDF

Info

Publication number
CA2325354A1
CA2325354A1 CA002325354A CA2325354A CA2325354A1 CA 2325354 A1 CA2325354 A1 CA 2325354A1 CA 002325354 A CA002325354 A CA 002325354A CA 2325354 A CA2325354 A CA 2325354A CA 2325354 A1 CA2325354 A1 CA 2325354A1
Authority
CA
Canada
Prior art keywords
irf
ser
modified
protein
regulatory factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002325354A
Other languages
English (en)
Inventor
John Hiscott
Rongtuan Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sir Mortimer B Davis Jewish General Hospita
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002234588A external-priority patent/CA2234588A1/fr
Application filed by Individual filed Critical Individual
Priority to CA002325354A priority Critical patent/CA2325354A1/fr
Publication of CA2325354A1 publication Critical patent/CA2325354A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des protéines du facteur de régulation de l'interféron ou protéines IRF qui ont été modifiées dans le domaine des terminaisons carboxy (domaine de transactivation), par modification des sites sérine et/ou thréonine. La modification peut s'obtenir par phosphorylation de la sérine et/ou de la thréonine, ou par remplacement des résidus sérine et/ou thréonine, lesquels résidus portent des chaînes latérales acides, de préférence des chaînes latérales contenant de l'acide carboxylique, notamment les résidus d'acide aspartique ou d'acide glutamique. De telles protéines modifiées peuvent être des mutants des IRF-3 et IRF-7, y compris des protéines chimériques portant des parties aussi bien de IRF-3 et IRF-7. Ces protéines peuvent aussi être une protéine IRF-3 à modification (phosphorylation) post-translationnelle, laquelle phosphorylation a été induite par l'infection à virus Sendai. De façon plus spécifique, la présente invention concerne une protéine du facteur régulateur de l'interféron (IRF), laquelle protéine comporte au moins, dans le domaine de la terminaison carboxy, un site phosphoaccepteur de sérine ou thréonine modifiée, l'activation du gène de la cytokine par l'IRF modifié étant augmentée, par rapport à l'activation du gène de la cytokine, d'une protéine IRF de type sauvage correspondante. L'invention concerne également des compositions pharmaceutiques contenant la protéine IRF, ainsi que l'utilisation de la protéine. L'invention concerne enfin une séquence de nucléotides codant la protéine ainsi que des compositions pharmaceutiques contenant une telle séquence.
CA002325354A 1998-04-07 1999-04-07 Formes hautement actives de proteines du facteur de regulation de l'interferon Abandoned CA2325354A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002325354A CA2325354A1 (fr) 1998-04-07 1999-04-07 Formes hautement actives de proteines du facteur de regulation de l'interferon

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA2,234,588 1998-04-07
CA002234588A CA2234588A1 (fr) 1998-04-07 1998-04-07 Phosphorylation induit par virus de l'interferon regulatoire de facteur-3
CA002325354A CA2325354A1 (fr) 1998-04-07 1999-04-07 Formes hautement actives de proteines du facteur de regulation de l'interferon
PCT/CA1999/000314 WO1999051737A1 (fr) 1998-04-07 1999-04-07 Formes hautement actives de proteines du facteur de regulation de l'interferon

Publications (1)

Publication Number Publication Date
CA2325354A1 true CA2325354A1 (fr) 1999-10-14

Family

ID=25680127

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002325354A Abandoned CA2325354A1 (fr) 1998-04-07 1999-04-07 Formes hautement actives de proteines du facteur de regulation de l'interferon

Country Status (1)

Country Link
CA (1) CA2325354A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114874313A (zh) * 2015-11-16 2022-08-09 Ubi蛋白公司 用于延长蛋白质半衰期的方法
EP3740198A4 (fr) * 2018-01-18 2023-08-09 Fred Hutchinson Cancer Center Modification des états inflammatoires de cellules immunitaires in vivo par modulation des états d'activation cellulaire
US11872195B2 (en) 2016-04-14 2024-01-16 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114874313A (zh) * 2015-11-16 2022-08-09 Ubi蛋白公司 用于延长蛋白质半衰期的方法
US11872195B2 (en) 2016-04-14 2024-01-16 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
EP3740198A4 (fr) * 2018-01-18 2023-08-09 Fred Hutchinson Cancer Center Modification des états inflammatoires de cellules immunitaires in vivo par modulation des états d'activation cellulaire

Similar Documents

Publication Publication Date Title
Lin et al. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation
Sangfelt et al. Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-α in hematopoietic cell lines
Mamane et al. Interferon regulatory factors: the next generation
Matsumura et al. Thrombopoietin-induced differentiation of a human megakaryoblastic leukemia cell line, CMK, involves transcriptional activation of p21 WAF1/Cip1 by STAT5
Pitha et al. Role of the interferon regulatory factors (IRFs) in virus-mediated signaling and regulation of cell growth
D'Souza et al. Nuclear factor κB-dependent activation of the antiapoptotic bfl-1 gene by the Epstein-Barr virus latent membrane protein 1 and activated CD40 receptor
US20060286091A1 (en) RelA-ASSOCIATED INHIBITOR, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF
Roulston et al. Chronic human immunodeficiency virus type 1 infection stimulates distinct NF-kappa B/rel DNA binding activities in myelomonoblastic cells
US20050181420A1 (en) Polypeptide that interacts with heat shock proteins
US20030077262A1 (en) Methods and compositions for modulating apoptosis
US6338949B1 (en) Nucleic acids encoding receptor recognition factor stat4 and methods of use thereof
Kieser et al. Protein kinase C-zeta reverts v-raf transformation of NIH-3T3 cells.
EP1506784A1 (fr) L'identification de facteurs bloquant la mort cellulaire programmée ou l'apoptose par ciblage de JNK
CA2325354A1 (fr) Formes hautement actives de proteines du facteur de regulation de l'interferon
US20130330738A1 (en) Sumoylation Control Agent and Uses Thereof
US20020147147A1 (en) Nucleic acid molecules encoding a protein interacting with the chemokine receptor CCR5 or other chemokine receptor family members
AU2001274772B2 (en) Inhibitory PAS domain protein (IPAS) and screening methods related to angiogenesis and tumor progression
US7053194B2 (en) Compositions and methods for p53-mediated repression of gene expression
WO1999051737A1 (fr) Formes hautement actives de proteines du facteur de regulation de l'interferon
US6680366B1 (en) Nucleotide sequence encoding a modulator of NF-κB
AU8072194A (en) Receptor recognition factors, protein sequences and methods of use thereof
CA2132317A1 (fr) Facteurs de reconnaissance des recepteurs de l'ifn, sequences proteiques et methodes d'application
AU2001274772A1 (en) Inhibitory PAS domain protein (IPAS) and screening methods related to angiogenesis and tumor progression
US7094873B1 (en) Polypeptide that interacts with heat shock proteins
US7638304B2 (en) Hybrid fusion protein transcription regulator to induce interferon target gene expression

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued